Akash Tewari
Stock Analyst at Jefferies
(1.58)
# 3,426
Out of 4,996 analysts
60
Total ratings
33.33%
Success rate
-1.46%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $83 → $96 | $64.09 | +49.79% | 2 | Sep 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $813 → $831 | $563.90 | +47.37% | 5 | Aug 27, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $26 | $12.43 | +109.17% | 1 | Aug 25, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $8.27 | +20.92% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $44.12 | +54.13% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $53.85 | +76.42% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $98.08 | +52.94% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $5.17 | +209.48% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $142.00 | +33.10% | 2 | Aug 19, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $80 | $22.39 | +257.30% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $994 → $1,015 | $724.54 | +40.09% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $27.89 | +79.28% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $38.21 | +96.28% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $16.24 | +90.89% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $23.76 | +64.14% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $7.90 | +127.85% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $712.03 | -27.95% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $7.64 | +135.60% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $78.56 | +59.11% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $16.60 | -33.73% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.66 | +924.10% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $50.40 | +48.81% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $424.23 | -64.41% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $39.04 | -28.28% | 3 | Oct 7, 2021 |
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $83 → $96
Current: $64.09
Upside: +49.79%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Buy
Price Target: $813 → $831
Current: $563.90
Upside: +47.37%
Crescent Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $26
Current: $12.43
Upside: +109.17%
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $8.27
Upside: +20.92%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $44.12
Upside: +54.13%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $53.85
Upside: +76.42%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $98.08
Upside: +52.94%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $5.17
Upside: +209.48%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $142.00
Upside: +33.10%
Apellis Pharmaceuticals
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $22.39
Upside: +257.30%
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $724.54
Upside: +40.09%
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $27.89
Upside: +79.28%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $38.21
Upside: +96.28%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $16.24
Upside: +90.89%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $23.76
Upside: +64.14%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $7.90
Upside: +127.85%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $712.03
Upside: -27.95%
Jun 7, 2023
Initiates: Buy
Price Target: $18
Current: $7.64
Upside: +135.60%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $78.56
Upside: +59.11%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $16.60
Upside: -33.73%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.66
Upside: +924.10%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $50.40
Upside: +48.81%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $424.23
Upside: -64.41%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $39.04
Upside: -28.28%